88 related articles for article (PubMed ID: 15878877)
1. Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism.
Lookene A; Beckstead JA; Nilsson S; Olivecrona G; Ryan RO
J Biol Chem; 2005 Jul; 280(27):25383-7. PubMed ID: 15878877
[TBL] [Abstract][Full Text] [Related]
2. Biogenesis of apolipoprotein A-V and its impact on VLDL triglyceride secretion.
Blade AM; Fabritius MA; Hou L; Weinberg RB; Shelness GS
J Lipid Res; 2011 Feb; 52(2):237-44. PubMed ID: 21115968
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the structure-function properties of wild-type human apoA-V and a C-terminal truncation associated with elevated plasma triglycerides.
Stankov S; Vitali C; Park J; Nguyen D; Mayne L; Englander SW; ; Levin MG; Vujkovic M; Hand NJ; Phillips MC; Rader DJ
medRxiv; 2023 Feb; ():. PubMed ID: 36865344
[TBL] [Abstract][Full Text] [Related]
4. Enhanced binding of apolipoprotein A-I variants associated with hypertriglyceridemia to triglyceride-rich particles.
Gorshkova IN; Atkinson D
Biochemistry; 2011 Mar; 50(12):2040-7. PubMed ID: 21288012
[TBL] [Abstract][Full Text] [Related]
5. Increased effect of fucoidan on lipoprotein lipase secretion in adipocytes.
Yokota T; Nagashima M; Ghazizadeh M; Kawanami O
Life Sci; 2009 Apr; 84(15-16):523-9. PubMed ID: 19302807
[TBL] [Abstract][Full Text] [Related]
6. Combined action of albumin and heparin regulates lipoprotein lipase oligomerization, stability, and ligand interactions.
Risti R; Gunn KH; Hiis-Hommuk K; Seeba NN; Karimi H; Villo L; Vendelin M; Neher SB; Lõokene A
PLoS One; 2023; 18(4):e0283358. PubMed ID: 37043509
[TBL] [Abstract][Full Text] [Related]
7. Role of Conserved Proline Residues in Human Apolipoprotein A-IV Structure and Function.
Deng X; Walker RG; Morris J; Davidson WS; Thompson TB
J Biol Chem; 2015 Apr; 290(17):10689-702. PubMed ID: 25733664
[TBL] [Abstract][Full Text] [Related]
8. Interactions of variants of human apolipoprotein A-I with biopolymeric model matrices. Effect of collagen and heparin.
Rosú SA; Aguilar J; Urbano BF; Tarraga WA; Ramella NA; Longo GS; Finarelli GS; Sanchez Donoso SA; Tricerri MA
Arch Biochem Biophys; 2023 Dec; 750():109805. PubMed ID: 37913855
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein A-I anti-tumor activity targets cancer cell metabolism.
Zamanian-Daryoush M; Lindner DJ; Buffa J; Gopalan B; Na J; Hazen SL; DiDonato JA
Oncotarget; 2020 May; 11(19):1777-1796. PubMed ID: 32477466
[TBL] [Abstract][Full Text] [Related]
10. Carboxyl-terminal sequences in APOA5 are important for suppressing ANGPTL3/8 activity.
Chen YQ; Yang Y; Zhen EY; Beyer TP; Li H; Wen Y; Ehsani M; Jackson N; Xie K; Jung H; Scheithauer JL; Kumari A; Birrane G; Russell AM; Balasubramaniam D; Liao Z; Siegel RW; Qian Y; Ploug M; Young SG; Konrad RJ
Proc Natl Acad Sci U S A; 2024 Apr; 121(17):e2322332121. PubMed ID: 38625948
[TBL] [Abstract][Full Text] [Related]
11. Sequence Analysis of Six Candidate Genes in Miniature Schnauzers with Primary Hypertriglyceridemia.
Tate NM; Underwood M; Thomas-Hollands A; Minor KM; Cullen JN; Friedenberg SG; Mickelson JR; Xenoulis PG; Steiner JM; Furrow E
Genes (Basel); 2024 Jan; 15(2):. PubMed ID: 38397183
[TBL] [Abstract][Full Text] [Related]
12. The pathogenic mutations of APOA5 in Chinese patients with hyperlipidemic acute pancreatitis.
Liu Y; Dai S; Qin S; Zhou J; Wang Z; Yin G
Lipids Health Dis; 2024 Feb; 23(1):44. PubMed ID: 38331899
[TBL] [Abstract][Full Text] [Related]
13. Genetic variation in apolipoprotein A-V in hypertriglyceridemia.
Perera SD; Hegele RA
Curr Opin Lipidol; 2024 Apr; 35(2):66-77. PubMed ID: 38117614
[TBL] [Abstract][Full Text] [Related]
14. Hypertriglyceridemia in Apoa5-/- mice results from reduced amounts of lipoprotein lipase in the capillary lumen.
Yang Y; Beigneux AP; Song W; Nguyen LP; Jung H; Tu Y; Weston TA; Tran CM; Xie K; Yu RG; Tran AP; Miyashita K; Nakajima K; Murakami M; Chen YQ; Zhen EY; Kim JR; Kim PH; Birrane G; Tontonoz P; Ploug M; Konrad RJ; Fong LG; Young SG
J Clin Invest; 2023 Dec; 133(23):. PubMed ID: 37824203
[TBL] [Abstract][Full Text] [Related]
15. The Link between Magnesium Supplements and Statin Medication in Dyslipidemic Patients.
Nartea R; Mitoiu BI; Ghiorghiu I
Curr Issues Mol Biol; 2023 Apr; 45(4):3146-3167. PubMed ID: 37185729
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein size is a main determinant for the rate of hydrolysis by exogenous LPL in human plasma.
Kovrov O; Landfors F; Saar-Kovrov V; Näslund U; Olivecrona G
J Lipid Res; 2022 Jan; 63(1):100144. PubMed ID: 34710432
[TBL] [Abstract][Full Text] [Related]
17. Apolipoproteins in vascular biology and atherosclerotic disease.
Mehta A; Shapiro MD
Nat Rev Cardiol; 2022 Mar; 19(3):168-179. PubMed ID: 34625741
[TBL] [Abstract][Full Text] [Related]
18. The Importance of Lipoprotein Lipase Regulation in Atherosclerosis.
Kumari A; Kristensen KK; Ploug M; Winther AL
Biomedicines; 2021 Jul; 9(7):. PubMed ID: 34356847
[TBL] [Abstract][Full Text] [Related]
19. Triglyceride-rich lipoprotein binding and uptake by heparan sulfate proteoglycan receptors in a CRISPR/Cas9 library of Hep3B mutants.
Anower-E-Khuda F; Singh G; Deng Y; Gordts PLSM; Esko JD
Glycobiology; 2019 Jul; 29(8):582-592. PubMed ID: 31094413
[TBL] [Abstract][Full Text] [Related]
20. Critical Role of SREBP-1c Large-VLDL Pathway in Environment-Induced Hypertriglyceridemia of Apo AV Deficiency.
Takanashi M; Kimura T; Li C; Tanaka M; Matsuhashi A; Yoshida H; Noda A; Xu P; Takase S; Okazaki S; Iizuka Y; Kumagai H; Ikeda Y; Gotoda T; Takahashi M; Yagyu H; Ishibashi S; Yamauchi T; Kadowaki T; Liang G; Okazaki H
Arterioscler Thromb Vasc Biol; 2019 Mar; 39(3):373-386. PubMed ID: 30700132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
